# NeuroOne Reports Q4 Revenue Growth at Top End of FY2026 Guidance

- URL: https://stocks.freetheai.org/news/neuroone-reports-q4-revenue-growth-at-top-end-of-fy2026-guidance-45509d
- Published: 2026-10-12T11:00:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:NMTC](https://stocks.freetheai.org/symbols/NASDAQ-NMTC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

NeuroOne Medical Technologies Corporation (NMTC) announced preliminary fourth-quarter product revenue of approximately $3.8 million, representing a 38.4% increase compared to the same period last year. Full-year product revenue for fiscal 2026 reached about $10.5 million, marking a 15.6% annual rise and landing at the top of the company's previous financial outlook. Following the update, the company's shares rose 3.70% to $1.12.

The top-of-guidance sales performance highlights steady commercial adoption of the company's medical electrode products. In addition to sales growth, the firm secured a research subaward of roughly $200,000 supported by the National Institutes of Health. Running through April 30, 2027, the funding supports development of neurotransmitter sensing capabilities using sEEG electrodes, with further financial support anticipated over the next two years.

Investors will monitor the final release of complete fiscal year 2026 financial results, which are expected to be published in December 2026. Market participants will also track progress on the NIH-backed research program as the company expands its technology pipeline.

## Key points

- Preliminary Q4 product revenue rose 38.4% year-over-year to approximately $3.8 million.
- Full-year fiscal 2026 product revenue reached roughly $10.5 million, hitting the top end of guidance.
- Secured an NIH-backed research subaward of about $200,000 through April 2027 for sEEG electrodes.
- Complete financial results for fiscal year 2026 are scheduled for release in December 2026.

## Questions and answers

### What was NeuroOne's preliminary revenue for Q4 and FY2026?

NeuroOne reported preliminary Q4 product revenue of about $3.8 million, up 38.4% YoY, and full-year FY2026 product revenue of roughly $10.5 million, up 15.6% YoY.

### What grant did NeuroOne secure?

NeuroOne secured an NIH-backed research subaward of approximately $200,000 through April 30, 2027, to develop neurotransmitter sensing with sEEG electrodes.

### When will NeuroOne release its full FY2026 financial results?

The company expects to release its complete financial results for fiscal year 2026 in December 2026.